Do you want to read an article? Please log in or register.
Pembrolizumab in Combination With Platinum-Based Chemotherapy in Patients With Recurrent EGFR and ALK Gene Altered Non-Small-Cell Lung Cancer (NSCLC)
Lung Cancer
Related content
Lung Cancer
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial
Lancet Oncol
Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N, Popat S, Fang W, Luo Y, Li W, He Z, Zhao H, Li M, Song Q, Zhao H, El Darsa H, Monnet I, Cobo Dols M, García Campelo R, Jotte R, Berz D, Spira A, Pérol M, Nagasaka M, West H, Styles L, Li J, Clow F, Goldman J, Zhang L
doi: 10.1016/S1470-2045(26)00282-2
Lung Cancer
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Adv Ther
Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S
doi: 10.1007/s12325-025-03408-z
RECOMMENDED
Lung Cancer
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Kinehara Y, Matsumoto K, Shiroyama T, Komuta K, Tamiya M, Nishino K, Tamiya A, Kuge T, Uchida J, Suzuki H, Yamamoto S, Tobita S, Niki T, Tetsumoto S, Morimura O, Osa A, Minami T, Nagatomo I, Takeda Y, Kijima T, Kumanogoh A
doi: 10.1016/j.lungcan.2026.109336
Lung Cancer
First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases
Lung Cancer
Frehner L, Schär S, Hayoz S, Petermichl V, Speicher P, I Rothschild S, Mauti LA, König D, Finazzi T, Froesch P, Marini S, Allemann A, Mark M, Janthur WD, Stamatiou A, Metaxas Y, Ermiş E, Wagner F, Früh M, Schmid S
doi: 10.1016/j.lungcan.2025.108813
Lung Cancer
Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA study
Lung Cancer
Supiot R, Gherardi A, du Manoir de Juaye L, Doghri O, Sivignon M, Duruisseaux M, Chouaid C
doi: 10.1016/j.lungcan.2025.108885
RECOMMENDED
Lung Cancer
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Liu G, Abrahami D, Ramachandran P, Messina R, Rifi N, Yang H, Chai X, Li B, Ramaswamy K, Iyengar P, Pennell NA, Shaw AT
doi: 10.1016/j.lungcan.2025.108858
Lung Cancer
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial
Lung Cancer
Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL
doi: 10.1016/j.lungcan.2026.109385
COMMENTED
Lung Cancer
Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
JAMA Oncol
Rousseau A, Foulon S, Planchard D, Remon J, Barlesi F, Lavaud P, Frelaut M, Aldea M, Parisi C, Gazzah A, Le Pechoux C, Botticella A, Levy A, Simon-Tillaux N, Michiels S, Besse B
doi: 10.1001/jamaoncol.2026.0669
Lung Cancer
CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46)
Lung Cancer
Martin LW, Wang X, Kozono D, Urbanic J, Graziano S, Osarogiagbon R, Mehran R, Wain J, Bestvina C, Wolf S, Patel JD, Stinchcombe T
doi: 10.1016/j.lungcan.2026.109374